## ACLX: Arcellx, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.2% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($63.72)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Arcellx Inc. (ACLX) Stock Price | Live Quotes & Charts | NASDAQ**
- Source: StocksToTrade | 20251208T191005 | Bullish | Relevance: 99%
-  This article provides live stock quotes and charts for Arcellx Inc. (ACLX) on NASDAQ. It shows the current stock price, daily change, and includes a candlestick line chart. The article also touches on analyst ratings and earnings, noting a lack of information for Arcellx Inc.

**2. Trading the Move, Not the Narrative: (ACLX) Edition**
- Source: Stock Traders Daily | 20251207T161600 | Somewhat-Bullish | Relevance: 98%
-  An analysis of Arcellx Inc. (NASDAQ: ACLX) reveals a mid-channel oscillation pattern, with weak near and mid-term sentiment contrasting a strong long-term positive outlook. The article presents an exceptional risk-reward setup targeting a 17.6% gain against 0.3% risk and outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles and holding periods for ACLX.

**3. Arcellx announces new data for its iMMagine-1 study in patients with RRMM**
- Source: TipRanks | 20251207T172055 | Bullish | Relevance: 98%
-  Arcellx (ACLX) announced positive new data from its pivotal Phase 2 iMMagine-1 study for anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma (RRMM). The data, presented at the 67th American Society of Hematology Annual Meeting, showed a 96% overall response rate and high rates of complete response and MRD negativity. The therapy demonstrated strong progression-free and overall survival rates over 24 months, with median PFS and OS not yet reached.

**4. Arcellx stock soars after positive multiple myeloma therapy data**
- Source: Investing.com | 20251208T131005 | Bullish | Relevance: 98%
-  Arcellx Inc (NASDAQ:ACLX) stock surged over 13% in premarket trading after reporting compelling data from its pivotal Phase 2 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma. The therapy showed high overall response rates, profound complete response rates, and significant progression-free and overall survival rates, with no new safety concerns. Arcellx, in partnership with Gilead's Kite, plans a commercial launch in 2026.

**5. Arcellx (NASDAQ:ACLX) Given Buy Rating at Canaccord Genuity Group**
- Source: MarketBeat | 20251208T181005 | Somewhat-Bullish | Relevance: 98%
- Canaccord Genuity Group has reiterated a "Buy" rating on Arcellx (NASDAQ:ACLX), setting a price target of $130, which suggests a potential upside of over 70%. Despite recent weak earnings and insider share sales, institutional investors hold a significant majority of the stock. Arcellx has a "Moderate Buy" consensus rating from analysts, with an average target price of $115.50.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Canaccord Genui | $130 | $130 | 0% |
| 2025-12-08 | Needham | $105 | $105 | 0% |
| 2025-11-18 | Wolfe Research | $0 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Canaccord Genui | main | Buy |
| 2025-12-08 | Needham | reit | Buy |
| 2025-11-18 | Wolfe Research | init | Peer Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 9 ($2.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 1 / 5 |

**Top Holders:**
- Gilead Sciences Inc: 11.6% (0.0%)
- T. Rowe Price Invest: 11.0% (+226.8%)
- FMR, LLC: 10.0% (-3.5%)
- Paradigm Biocapital : 8.0% (0.0%)
- Vanguard Group Inc: 6.8% (-1.0%)

### Key Risks

1. Elevated short interest (13.9%): bears positioning against stock.
2. Near-term weakness: 11.7% below SMA50 despite long-term uptrend.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_10 improving +17.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.49). Revenue growth strong at 288% YoY. Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (1 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.3B |
| Beta | 0.34 |
| 52W Range | $47.86 - $94.07 |
| Short Interest | 13.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -15.5% to 2.2% (+17.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.8pp (needs >3.0% for momentum thesis). MRS_5 at 4.5% confirms short-term momentum alignment. Outperforming sector by 5.6pp, stock-specific strength. Long-term uptrend intact (above SMA200 at 1.04x) but short-term weakness (below SMA20). MACD histogram bearish (-1.13), momentum weakening. RSI neutral at 42.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.18% (CS: 75) | Neutral |
| RSI_14 | 41.8 | Neutral |
| MACD Histogram | -1.13 | Bearish |
| vs SMA20 | 0.920x | Below |
| vs SMA50 | 0.883x | Below |
| vs SMA200 | 1.038x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $74.08
- **Stop Loss:** $63.72 (14.0% risk)
- **Target:** $84.44 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 48
- **Position Value:** $3,555.84
- **Portfolio %:** 3.56%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-26 (Est: $-1.06)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.03 | $-0.99 | +4.1% |
| 2025Q2 | $-1.03 | $-0.94 | +8.9% |
| 2025Q1 | $-0.74 | $-1.13 | -53.0% |
| 2024Q4 | $-0.47 | $-0.87 | -83.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*